Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 26,816 shares of the company’s stock, valued at approximately $634,000.
Several other large investors have also made changes to their positions in DYN. Bank of New York Mellon Corp raised its position in Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after acquiring an additional 698 shares in the last quarter. KBC Group NV raised its holdings in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Virtue Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock worth $834,000 after purchasing an additional 981 shares in the last quarter. Finally, Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the third quarter worth $36,000. Institutional investors own 96.68% of the company’s stock.
Insiders Place Their Bets
In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 6,237 shares of company stock worth $77,760 over the last 90 days. Corporate insiders own 20.77% of the company’s stock.
Dyne Therapeutics Stock Up 2.2 %
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on DYN. Chardan Capital reiterated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Piper Sandler dropped their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $48.85.
View Our Latest Stock Report on Dyne Therapeutics
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Stories
- Five stocks we like better than Dyne Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Can TikTok Stock Picks Really Make You Rich?
- P/E Ratio Calculation: How to Assess Stocks
- The “Quality” Rotation: Back to Basics Investing
- How to trade penny stocks: A step-by-step guide
- Occidental Petroleum: 4 Reasons to Love These Prices
Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.